WO2022124934A1 - Inhibition de l'expression de microarn-24, microarn-125 athérogènes et induction d'expression de microarn-126, microarn-222 et microarn-let7b anti-athérogènes - Google Patents
Inhibition de l'expression de microarn-24, microarn-125 athérogènes et induction d'expression de microarn-126, microarn-222 et microarn-let7b anti-athérogènes Download PDFInfo
- Publication number
- WO2022124934A1 WO2022124934A1 PCT/RU2021/000566 RU2021000566W WO2022124934A1 WO 2022124934 A1 WO2022124934 A1 WO 2022124934A1 RU 2021000566 W RU2021000566 W RU 2021000566W WO 2022124934 A1 WO2022124934 A1 WO 2022124934A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microrna
- expression
- atherogenic
- let7b
- blood plasma
- Prior art date
Links
- 230000000923 atherogenic effect Effects 0.000 title claims abstract description 16
- 230000000489 anti-atherogenic effect Effects 0.000 title claims abstract description 14
- 230000001939 inductive effect Effects 0.000 title claims abstract description 5
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 5
- 239000002679 microRNA Substances 0.000 claims abstract description 25
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 24
- 108700011259 MicroRNAs Proteins 0.000 claims abstract description 19
- 210000002381 plasma Anatomy 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 4
- 239000006286 aqueous extract Substances 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 241000125175 Angelica Species 0.000 abstract description 24
- 239000000284 extract Substances 0.000 abstract description 17
- 230000037396 body weight Effects 0.000 abstract description 4
- 230000001973 epigenetic effect Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 230000037406 food intake Effects 0.000 abstract 2
- 108091070501 miRNA Proteins 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108091007423 let-7b Proteins 0.000 description 2
- 102000008089 Myosin-Light-Chain Kinase Human genes 0.000 description 1
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 108010041788 rho-Associated Kinases Proteins 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
Definitions
- the invention relates to the field of clinical medicine, namely to the possibility of influencing the expression profile of certain microRNAs in human blood plasma by taking angelica extract, which will make it possible to use angelica extract in the future as a protective agent against the action of certain epigenetic atherogenic factors in human blood plasma.
- the technical result of the claimed method is the possibility of influencing the expression profile of certain miRNAs (miRNA-24, -125, -126, -222, -let7b) in blood plasma by inhibiting the expression of atherogenic microRNAs (miRNA-24, -125) and inducing the expression of antiatherogenic miRNA (miRNA-126, -222, -let7b) by taking angelica extract.
- the above technical result is achieved due to the fact that the method includes the sequential execution of the following steps: 1) obtaining an extract of angelica; 2) taking the resulting angelica extract, 5 drops per 10 kg of body weight daily for 4 weeks.
- An extract of angelica is obtained by drying the roots of the angelica plant for a week at a temperature of 24 ⁇ 1 ° C, then the dried roots are crushed to a powder, then 100 ml of crushed angelica are added to 100 ml of distilled water, stirred, then the resulting mixture is boiled in a water bath for 1-3 hours, until the volume of liquid decreases by 10 times, it is centrifuged at 15,000 rpm for 30 minutes at a temperature of 24 ⁇ 1 ° C, then the resulting supernatant is filtered on a Whatman No.
- miRNAs were isolated from peripheral venous blood (5 ml, collected in a vacuum tube with anticoagulant) using RNeasy Mini Kits (Qiagen, Germany), then reverse transcription was performed using miScript II RT kits (Qiagen, Germany). Germany) and real-time PCR with primers to miRNA-24, 125, 126, 222, let-7b, 16.
- the expression level is given relative to the expression level of miRNA 16 (miRNeasy Mini Kit, miScript II RT Kit, Qiagen, Germany).
- the microRNA values are presented as the ratio of the expression level of the studied microRNA, presented as the number of copies of the studied microRNA/ ⁇ l, to the expression level of the microRNA!
- miRNA copy number 16/ ⁇ l also represented as miRNA copy number 16/ ⁇ l. This approach is generally accepted for reflecting the dynamics of microRNA expression levels, since the expression level of microRNA 16 is stable relative to the expression levels of other microRNAs and can act as a reference, relative to which the expression levels of other microRNAs are evaluated, and the expression levels of microRNAs between different objects (cell lines, cultures, living organisms) can be assessed.
- the level of expression of atherogenic miRNAs in blood plasma after 4 weeks of taking angelica extract at a dosage of 5 drops per 10 kg of body weight decreased: miRNA-24 decreased from 12.1 to 5.4 in a man and from 10.4 to 7.2 in a woman; miRNA-125 from 7.5 to 5.8 in men and from 7.6 to 6.0 in women.
- the level of expression of anti-atherogenic miRNAs in blood plasma after 4 weeks of taking angelica extract increased: miRNA-126 from 4.5 to 5.1 in men and from 5.1 to 6.6 in women; miRNA-222 from 3.8 to 6.7 in men and from 5.8 to 7.1 in women and let-7b from 2.2 to 4.9 in men and from 7.9 to 10.3 in women.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
L'invention concerne un procédé d'inhibition de l'expression de microARN-24, microARN-125 athérogènes et d'induction d'expression de microARN-126, microARN-222 et microARN-let7b anti-athérogènes dans le plasma sanguin humain. Cette invention se rapporte au domaine de la médecine clinique, notamment à la possibilité d'influer sur le profil d'expression de micro-ARN prédéterminés dans le plasma sanguin humain, consistant à administrer un extrait d'angélique, ce qui permet d'utiliser par la suite l'extrait d'angélique comme moyen de protection contre l'action de facteurs athérogènes épigénétiques dans le plasma sanguin humain. Le résultat technique de ce procédé consiste en la possibilité d'influer sur le profil d'expression de microARN prédéterminés (MicroARN -24, -125, -126, -222, -let7b) dans le plasma sanguin par l'inhibition de l'expression de microARN athérogènes (microARN-24, -125) et l'induction de l'expression de microARN anti-athérogènes (microARN-126, -222, -let7b) par la prise de l'extrait d'angélique. Ce résultat technique est obtenu du fait que le procédé consiste à réaliser successivement les étapes suivantes: 1) obtenir de l'extrait d'angélique; 2) prendre l'extrait d'angélique obtenu par 5 gouttelettes pour 10 kg de poids chaque jour pendant 4 semaines.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2020140927 | 2020-12-11 | ||
| RU2020140927A RU2752166C1 (ru) | 2020-12-11 | 2020-12-11 | Способ ингибирования экспрессии атерогенных микроРНК-24, микроРНК - 125 и индуцирования экспрессии антиатерогенных микроРНК-126, микроРНК -222, микроРНК -let7b в плазме крови человека |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022124934A1 true WO2022124934A1 (fr) | 2022-06-16 |
Family
ID=76989428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU2021/000566 WO2022124934A1 (fr) | 2020-12-11 | 2021-12-10 | Inhibition de l'expression de microarn-24, microarn-125 athérogènes et induction d'expression de microarn-126, microarn-222 et microarn-let7b anti-athérogènes |
Country Status (2)
| Country | Link |
|---|---|
| RU (1) | RU2752166C1 (fr) |
| WO (1) | WO2022124934A1 (fr) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040223942A1 (en) * | 2003-03-06 | 2004-11-11 | Kao Corporation | Skin aging-preventing or improving agent |
-
2020
- 2020-12-11 RU RU2020140927A patent/RU2752166C1/ru active
-
2021
- 2021-12-10 WO PCT/RU2021/000566 patent/WO2022124934A1/fr active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040223942A1 (en) * | 2003-03-06 | 2004-11-11 | Kao Corporation | Skin aging-preventing or improving agent |
Non-Patent Citations (3)
| Title |
|---|
| BOIKO N. V ET AL.: "Rol mikroRNK v reguliatsii aktivnosti genov u eukariot", VESTNIK JUZHNOGO NAUCHNOGO TSENTRA RAN, vol. 7, no. 3, 2011, pages 69 - 78 * |
| CHENGXU MA ET AL.: "The effects of Radix Angelica Sinensis and Radix Hedysari ultrafiltration extract on X -irradiation-induced myocardial fibrosis in rats", BIOMEDICINE & PHARMACOTHERAPY, vol. 112, 2019, pages 1 - 8 * |
| DRAGANOVA A. S. ET AL.: "Ekspressia mikroRNK-27a v syvorotke krovi u patsientov s ostrym koronamym sindromom bez podema segmenta ST, perenesshikh chreskozhnoe koronamoe vmeshatelstvo", ROSSYSKY KARDIOLOGICHESKY ZHUMAL, vol. 24, no. 2, 2019, pages 70 - 75 * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2752166C1 (ru) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2717497B2 (ja) | 酸性多糖類被覆コンドーム | |
| TW201625271A (zh) | 含有槲皮素配糖體之筋萎縮抑制劑 | |
| RU2697523C2 (ru) | Фармацевтическая композиция, содержащая силибин | |
| US20160051608A1 (en) | Anti-cancer extract and compounds | |
| KR20080080127A (ko) | 파세러스 불가리스 추출물, 그 용도 및 이를 함유하는배합물 | |
| US11173188B2 (en) | Orange peel ferments and preparations and applications thereof | |
| WO2022124934A1 (fr) | Inhibition de l'expression de microarn-24, microarn-125 athérogènes et induction d'expression de microarn-126, microarn-222 et microarn-let7b anti-athérogènes | |
| CN107847759A (zh) | 用于减少脂肪量的β‑羟基‑β‑甲基丁酸(HMB)的组合物和使用方法 | |
| CN111939179B (zh) | 眼镜蛇蛇毒或其提取物在制备降尿酸和/或抗痛风性关节炎的药物中的应用 | |
| WO2021243757A1 (fr) | Application pharmaceutique d'acide gallique | |
| MXPA05007440A (es) | Un metodo de tratamiento o profilaxis de sintomas de infeccion viral de herpes. | |
| CN109045016A (zh) | 缓解糖皮质激素副作用的方法 | |
| CN111358804B (zh) | Cynanoside H在制备防治乳腺癌的药物中的应用 | |
| CN111568997A (zh) | 一种治疗肥胖型脂肪肝的中药组合物及其制备方法 | |
| CN106163535B (zh) | 包含胡桃萃取物的抗肥胖剂 | |
| AU774877B2 (en) | Medicaments that contain xenogenic oligo- or/and polyribonucleotides | |
| RU2759806C1 (ru) | Способ снижения уровней экспрессии генов LRNN3, GRAP, VAMP5 | |
| WO2015002576A1 (fr) | Utilisation de l'homogénat de couvain de faux-bourdons adsorbé et de vitamine d3 ou de vitamines du groupe d et/ou de leurs métabolites actifs pour la prévention et le traitement des maladies virales | |
| US20110224291A1 (en) | Skin external composition for inhibiting epidermal hyperproliferation and alleviating inflammatory skin diseases containing orthodihydroxyisoflavone derivatives | |
| CN114606236B (zh) | 一种翘芪复方中药汤剂来源的微小核糖核酸及其制备方法和应用 | |
| US6020325A (en) | Method for inhibiting replication of HIV | |
| KR20200135621A (ko) | 퀘르세틴-3-ｏ-글루쿠로니드를 유효성분으로 하는 비만 예방 및 치료소재 | |
| CN112220739B (zh) | 一种hpv病毒灭活敷料及其制备方法 | |
| WO2018052357A1 (fr) | Complément alimentaire pour soulager une inflammation chronique du côlon | |
| RU2203075C1 (ru) | Способ получения вещества из натурального меда |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21903937 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11202305571P Country of ref document: SG |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21903937 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22.11.2023) |